Pharsight

Drugs that contain Bortezomib

1. Bortezomib patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(8 years from now)

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

Family Patents

2. Bortezomib patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752164 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(18 years from now)

US11679119 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(18 years from now)

Market Authorisation Date: 27 July, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma; Treatment of adult patients with multiple myeloma

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

Family Patents

3. Velcade patents expiration

VELCADE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6713446

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 7 months ago)

US6958319

(Pediatric)

TAKEDA PHARMS USA Formulation of boronic acid compounds
Jul, 2022

(1 year, 7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity (PED) Apr 8, 2022

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

How can I launch a generic of VELCADE before it's drug patent expiration?
More Information on Dosage

VELCADE family patents

Family Patents